Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
323 participants
INTERVENTIONAL
2011-05-02
2023-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary hypothesis is that flow diversion can be performed with an "acceptable" immediate complication rate, defined as less than 15% morbidity and mortality, AND increase the number of patients experiencing successful therapy, defined as complete or near complete occlusion of the aneurysm from 75 to 90%, relative to best standard treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
International Subarachnoid Aneurysm Trial II
NCT01668563
Efficacy Trial of Intracranial Aneurysm Treatment Using Two Different Endovascular Techniques
NCT01084681
Middle Cerebral Artery Aneurysm Trial
NCT05161377
Trial on Endovascular Aneurysm Management
NCT00537134
International Retrospective Study of Pipeline Embolization Device
NCT01558102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intracranial aneurysms, particularly large/giant, fusiform or recurrent aneurysms are increasingly treated with flow diverters (FDs), a recently introduced and approved neurovascular device. While some rare cases may not be treated any other way, in most patients a more conventional, conservative, or validated approach such as coiling, parent vessel occlusion, or surgical clipping exists. Early series and registries of the use of FDs in various types of aneurysms have reported treatment-related morbidity and mortality ranging from 0 to 4 and 8% respectively, most often from delayed haemorrhage. Hence, although there is growing enthusiasm to use these powerful new tools, complications are increasingly reported.
Rationale and Hypothesis:
There is an urgent need to offer the new tool afforded by FDs to patients currently presenting with a difficult aneurysm, in a context that can offer protection from over-optimistic perspectives, fashion, learning curves and marketing. Only a randomized clinical trial can offer such protection as well as provide an answer to the question of which treatment option leads to better patient outcomes. The primary hypothesis is that flow diversion can be performed with an "acceptable" immediate complication rate, defined as less than 15% morbidity and mortality (modified Rankin Score \> 2 at 3 months), AND increase the number of patients experiencing successful therapy, defined as complete or near complete occlusion of the aneurysm from 75 to 90%.
Objectives:
Compare flow diversion (FD) to Best-Standard Treatment (BST) in the context of an RCT. BST may be any of the following: 1) conservative management; 2) coiling with or without high porosity stenting; 3) parent vessel occlusion with or without bypass; 4) surgical clipping; 5) enter a registry for FD, when the only treatment alternative is FD for compassionate use.
Methods:
Following randomization to FD or BST, patients will undergo the assigned intervention and be followed for 12 months. Clinical status will be recorded at discharge, at 1-3 months, and at 3-12 months. Angiographic evaluation will be recorded at 3-12 months. Adverse Events will be recorded immediately after the procedure and during the 12-month follow-up period. Patients in the FD registry will similarly be followed for 12 months. A total of 344 patients will be recruited in 20 centers worldwide. The trial is expected to last for 5 years.
Analysis:
Comparability between FD and BST groups will use descriptive statistics or frequency tables, independent ANOVAs or Mantel-Haentzel and chi-square tests. Comparison of primary outcome will use a z-test for independent proportions at 12 months. Safety data will be compared through independent t-tests or chi-square statistics. Logistic regression will be used to find variables capable of predicting success in both groups at 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
flow diversion
Flow diverters are low porosity braided endovascular stent devices. They can be used with or without coiling.
flow diversion
endovascular treatment with flow diversion including standard management of thrombo-embolic risk
Best standard treatment
Best standard treatment can by any of the standard management options: coiling, stenting plus coiling, surgical clipping, parent vessel occlusion, observation
conservative management
conservative management is watchful observation of the aneurysm until indication for intervention arises
endovascular coiling
standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
balloon parent vessel occlusion
sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
surgical clipping
clipping of the aneurysm following invasive brain surgery
Registry for flow diversion
Flow diversion when randomization between flow diversion and best standard treatment is not possible and the only alternative is flow diversion for compassionate use. In this case there will be no random allocation but the patient will be entered into a registry
flow diversion
endovascular treatment with flow diversion including standard management of thrombo-embolic risk
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
flow diversion
endovascular treatment with flow diversion including standard management of thrombo-embolic risk
conservative management
conservative management is watchful observation of the aneurysm until indication for intervention arises
endovascular coiling
standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
balloon parent vessel occlusion
sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
surgical clipping
clipping of the aneurysm following invasive brain surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Absolute contraindication to endovascular treatment or anesthesia.
* Patients unable to give informed consent.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre de Recherche du Centre Hospitalier de l'Université de Montréal
OTHER
Centre hospitalier de l'Université de Montréal (CHUM)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Raymond, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier de l'Université de Montréal - Hôpital Notre Dame
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alberta Hospital
Edmonton, Alberta, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Centre Hospitalier de l'Université de Montréal - Hôpital Notre Dame
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Raymond J, Gentric JC, Darsaut TE, Iancu D, Chagnon M, Weill A, Roy D. Flow diversion in the treatment of aneurysms: a randomized care trial and registry. J Neurosurg. 2017 Sep;127(3):454-462. doi: 10.3171/2016.4.JNS152662. Epub 2016 Nov 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CE10.206
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.